Showing 2521-2530 of 3039 results for "".
- Hilco Vision Acquires Simovision BVhttps://modernod.com/news/hilco-vision-acquires-belgium-and-netherlands-based-simovision-bv/2480473/Hilco Vision has acquired Simovision BV, effective November 17, 2021.
- Clearside Biomedical Features FDA-Approved Xipere in Multiple Presentations at AAO and American Uveitis Society Meetingshttps://modernod.com/news/clearside-biomedical-features-fda-approved-xipere-in-multiple-presentations-at-aao-and-american-uveitis-society-meetings/2480454/Clearside Biomedical announced that multiple presentations were given at the American Academy of Ophthalmology (AAO) 2021, which took place November 12-15, 2021 in New Orleans, LA. “Our presentations at AAO and AUS, combined with the positive data p
- Kala Pharmaceuticals Acquires Combangio, Maker of Regenerative Biotherapies for Severe Ocular Surface Diseaseshttps://modernod.com/news/kala-pharmaceuticals-acquires-combangio-maker-of-regenerative-biotherapies-for-severe-ocular-surface-diseases/2480449/Kala Pharmaceuticals announced that it has acquired Combangio, a private, clinical-stage company developing regenerative biotherapies for severe ocular surface diseases. Combangio is developing CMB-012, a novel investigational secretome therapy, now known as KPI-012, to address the complex w
- Oculis Announces Patient Dosing in its First Phase 3 Study With OCS-01 Investigational Topical Eye Drop for DMEhttps://modernod.com/news/oculis-announces-patient-dosing-in-its-first-phase-3-study-with-ocs-01-investigational-topical-eye-drop-for-dme/2480432/Oculis SA announced that the first patients have been dosed in its phase 3 DIAMOND trial evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME). OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone (DSN
- iVeena Announces Successful Completion of Pre-IND Meeting with FDAhttps://modernod.com/news/iveena-announces-successful-completion-of-pre-ind-meeting-with-fda/2480426/iVeena Delivery Systems announced completion of a pre-investigational new drug (IND) meeting with the FDA regarding the development plan for a novel pharmacologic treatment of pediatric myopia. IVMED-85 enables physiologic crosslinking in the sclera an
- Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021https://modernod.com/news/oyster-point-pharma-to-present-data-at-the-american-academy-of-ophthalmology-annual-meeting-2021/2480417/Oyster Point Pharma announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) annual meeting 2021 being held in New Orleans, November 12–15, 2021. “The American Academy of Ophthalmology is the world’
- Alcon to Acquire Ivantis, Maker of the Hydrus Microstent for Surgical Glaucomahttps://modernod.com/news/alcon-to-acquire-ivantis-and-its-hydrus-microstent-for-surgical-glaucoma-strengthening-global-ophthalmology-portfolio/2480410/Alcon announced its intention to acquire Ivantis, developer and manufacturer of the Hydrus Microstent. The deal will strenghten Alcon's surgical glaucoma portfolio and allow it to enter the growing MIGS category. Under terms of the deal, Alcon will pay $475 million in upfr
- Ocular Therapeutix to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meetinghttps://modernod.com/news/ocular-therapeutix-to-present-data-at-the-american-academy-of-ophthalmology-aao-2021-virtual-annual-meeting/2480384/Ocular Therapeutix announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting being held November 12-15, 2021. “We are happy to have a large presence at AAO this year with six poster presentations in five different indicatio
- IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injuryhttps://modernod.com/news/iacta-pharmaceuticals-receives-us-department-of-defense-funding-of-1-million-to-conduct-preclinical-studies-of-ic-800-to-treat-pain-relief-for-eye-injury/2480382/IACTA Pharmaceuticals announced that the U.S. Army Medical Research Acquisition Activity (USAMRAA), a division of the Department of Defense, has granted a $1 million award to the company to fund preclinical studies of IC 800, a novel therapy for the topical treatment of ocular pain utilizing
- Luminopia Announces FDA Approval of Digital Therapeutic to Improve Vision in Children with Lazy Eyehttps://modernod.com/news/luminopia-announces-fda-approval-of-digital-therapeutic-to-improve-vision-in-children-with-lazy-eye/2480369/Luminopia announced that the FDA has granted de novo premarket approval for Luminopia One as a prescription therapy to improve vision in children with amblyopia (lazy eye), the leading cause of vision loss in children. Luminopia One is indicated for improvement in visual acuity in child